Krystal Biotech, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $KRYS in the last 30 days.
See all $KRYS insider activity →Krystal Biotech reported that KB113 showed over 80% lesion regression in a three-patient Gorlin syndrome pilot study, with both injected and non-injected lesions regressing. The treatment was well tolerated, with mild/moderate adverse events. The company is discussing advanced clinical development plans with the FDA.
Krystal Biotech, Inc. (KRYS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients t
Krystal Biotech (KRYS) reported $119.2M Q2 revenue from VYJUVEK, a gene therapy for DEB, up 24% YoY. The drug has a 95% gross margin and over 730 U.S. reimbursement approvals. The company's advantage may be durable due to its platform, manufacturing, and patient experience, but faces potential competition and pricing challenges.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning KRYS (Krystal Biotech, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent KRYS coverage spans financial news, insider activity and earnings.
Positive early‑stage data may boost investor sentiment and drive short‑term buying pressure.
Positive early‑stage data may lift the stock as investors price in proof‑of‑concept and potential FDA discussions.
The article questions the durability of Krystal's moat without presenting new data.
The update suggests modest near-term revenue growth with longer-term upside from new programs, but no immediate catalyst.
Insider sell after strong run; could signal profit‑taking.
AlphAI scores every news story that mentions KRYS with an AI model for sentiment and relevance, and aggregates insider trades from Krystal Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Krystal Biotech reported that KB113 showed over 80% lesion regression in a three-patient Gorlin syndrome pilot study, with both injected and non-injected lesions regressing. The treatment was well tolerated, with mild/moderate adverse events. The company is discussing advanced clinical development plans with the FDA.
1 min readKrystal Biotech, Inc. (KRYS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients t
2 min readKrystal Biotech (KRYS) reported $119.2M Q2 revenue from VYJUVEK, a gene therapy for DEB, up 24% YoY. The drug has a 95% gross margin and over 730 U.S. reimbursement approvals. The company's advantage may be durable due to its platform, manufacturing, and patient experience, but faces potential competition and pricing challenges.
2 min readKrystal Biotech (KRYS) presented at the Cantor Fitzgerald Global Healthcare Conference, highlighting its genetic medicines platform. The company reported three years of positive EPS, with VYJUVEK sales plateauing at $85M-$95M quarterly. International expansion is expected to drive growth, despite pricing pressures. Key pipeline updates include Hailey-Hailey disease, ocular programs, and a pulmonary cancer program. Shares closed at $345.55, down 0.73%.
3 min readEnovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.
3 min readKrishnan Suma (President, R&D) sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $359.32 ($354.54–$366.56, $8.98M total) across 13 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min readKrishnan Krish S (President and CEO) sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $359.32 ($354.54–$366.56, $8.98M total) across 13 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min readKrystal Biotech (KRYS) shares rose 12% since its last earnings report, outperforming the S&P 500. The company reported Q2 2026 EPS of $1.79, beating estimates, with revenues of $119.2M, up 24% YoY. Vyjuvek sales drove growth, and the company maintained its 2026 guidance. Analysts have upwardly revised estimates, but the stock's momentum and value scores are low.
2 min readInvesting.com reported major US insider trades disclosed Friday. Buys: PAL director Rohit Lal bought $272.5k; OTLK director/10% owner Ghiath Sukhtian bought about 2.5M shares and warrants for ~$2.5M; CLPR director Sam Levinson bought ~$488.8k; OPFI CEO Todd Schwartz bought ~$144k; OPEN CEO Kasra Nejatian bought ~$100k. Sells: CRWV 10% owner Magnetar sold ~$231.6M then ~$213.8M; ANET CEO Ullal trust sales ~$119.3M; SEPN RA Capital sold $63.45M; KRYS director Rossi sold ~$8.23M.
7 min readKrystal Biotech director Dino A. Rossi sold about 25,000 shares for roughly $8.23m on Aug. 14, 2026, per an SEC Form 4, at weighted average prices of $325.60 to $333.23. He also gifted 3,691 shares to a donor-advised fund. Krystal Biotech reported Q2 diluted EPS of $1.79 (vs $1.70 est.) and revenue of $119.2m (vs $122.3m est.).
3 min read
